Choosing the right patent portfolio strategy will aid in protecting your valuable biotech intellectual property.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
KSR Int'l Co. v. Teleflex, Inc., 550 U.S. 398 (2007)
Wang, S.-J. Nat. Biotechnol. 27, 1125–1126 (2009).
In re Fisher. 421 F.3d 1365 (2005).
Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co. 598 F.3d 1336 (2010).
Simon, B.M. & Scott, C.T. Nat. Biotechnol. 29, 229–230 (2011).
Kimberly-Clark Corp. v. Johnson & Johnson. 745 F.2d 1437 (1984).
Elias, S. & Stim, R. Patent, Copyright & Trademark (Nolo, Berkeley, CA, 2003).
Goldenson, D. Nat. Biotechnol. 27, 538–541 (2009).
Palazzoli, F. et al. Nat. Biotechnol. 29, 593–597 (2011).
Granstrand, O. The Economics and Management of Intellectual Property (Edward Elgar, Cheltenham, UK, 1999).
Wang, S.-J. Hum. Vaccin. 7, 569–573 (2011).
Wang, S.-J. Hum. Vaccin. 7, 474–476 (2011).
Wang, S.-J. Nat. Biotechnol. 26, 519–522 (2008).
Boyer, H.W. & Cohen, S.N. US Patent 4,237,224 (1980).
Goldstein, H. IEEE Spectr. 43, 44–47 (2006).
Le, J. & Vilcek, J. Lab. Invest. 61, 588–602 (1989).
Vilela, E.G. et al. World J. Gastroenterol. 18, 872–881 (2012).
Kamm, M.A. et al. Inflamm. Bowel Dis. 17, 2366–2391 (2011).
Present, D.H. et al. Ann. Intern. Med. 111, 641–649 (1989).
Acknowledgements
This work is supported in part by the National Science Council (NSC 101-2325-B-075-003, 100-2221-E-075-001, 101-2221-E-075-001) and Taipei Veterans General Hospital (V101C-061, V102C-068), Republic of China.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Wang, SJ. Patent portfolios for biotech inventions. Nat Biotechnol 31, 501–503 (2013). https://doi.org/10.1038/nbt.2598
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2598
This article is cited by
-
Commercialization of regenerative-medicine therapies
Nature Reviews Bioengineering (2023)